Translating TRAIL-receptor targeting agents to the clinic

被引：66
作者：
den Hollander, Martha W. [1 ]
Gietema, Jourik A. [1 ]
de Jong, Steven [1 ]
Walenkamp, Annemiek M. E. [1 ]
Reyners, Anna K. L. [1 ]
Oldenhuis, Corina N. A. M. [1 ]
de Vries, Elisabeth G. E. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
来源：
CANCER LETTERS | 2013年 / 332卷 / 02期
关键词：
TRAIL; Clinical studies; Biomarkers; APOPTOSIS-INDUCING LIGAND; AGONISTIC MONOCLONAL-ANTIBODY; RECOMBINANT HUMAN APO2L/TRAIL; PHASE-I; FUSION PROTEIN; TUMOR-GROWTH; MAPATUMUMAB; COMBINATION; TRIAL; LEXATUMUMAB;
D O I：
10.1016/j.canlet.2012.04.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor Necrosis Factor (TNE)-Related Apoptosis-Inducing Ligand) by binding to the death receptors TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be safe and well tolerated. In this article, the clinical studies published to date will be reviewed. Also, future perspectives and biomarker studies for selecting patients that will benefit from these agents will be discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：194 / 201
页数：8
相关论文
共 73 条
  • [61] Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
    Trarbach, T.
    Moehler, M.
    Heinemann, V.
    Koehne, C-H
    Przyborek, M.
    Schulz, C.
    Sneller, V.
    Gallant, G.
    Kanzler, S.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (03) : 506 - 512
  • [62] Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor
    van der Sloot, Almer M.
    Tur, Vicente
    Szegezdi, Eva
    Mullally, Margaret M.
    Cool, Robbert H.
    Samali, Afshin
    Serrano, Luis
    Quax, Wim J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (23) : 8634 - 8639
  • [63] Van Laethem J., 2010, ASCO GASTR CANC S
  • [64] A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC
    Von Pawel, J.
    Harvey, J. H.
    Spigel, D. R.
    Dediu, M.
    Reck, M.
    Cebotaru, C. L.
    Kumm, E.
    Gallant, G.
    Fox, N.
    Camidge, D. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [65] Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
    Wagner, Klaus W.
    Punnoose, Elizabeth A.
    Januario, Thomas
    Lawrence, David A.
    Pitti, Robert M.
    Lancaster, Kate
    Lee, Dori
    von Goetz, Melissa
    Yee, Sharon Fong
    Totpal, Klara
    Huw, Ling
    Katta, Viswanatham
    Cavet, Guy
    Hymowitz, Sarah G.
    Amler, Lukas
    Ashkenazi, Avi
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1070 - 1077
  • [66] Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
    Wajant, H
    Moosmayer, D
    Wüest, T
    Bartke, T
    Gerlach, E
    Schönherr, U
    Peters, N
    Scheurich, P
    Pfizenmaier, K
    [J]. ONCOGENE, 2001, 20 (30) : 4101 - 4106
  • [67] Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
    Wakelee, H. A.
    Patnaik, A.
    Sikic, B. I.
    Mita, M.
    Fox, N. L.
    Miceli, R.
    Ullrich, S. J.
    Fisher, G. A.
    Tolcher, A. W.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (02) : 376 - 381
  • [68] Identification and characterization of a new member of the TNF family that induces apoptosis
    Wiley, SR
    Schooley, K
    Smolak, PJ
    Din, WS
    Huang, CP
    Nicholl, JK
    Sutherland, GR
    Smith, TD
    Rauch, C
    Smith, CA
    Goodwin, RG
    [J]. IMMUNITY, 1995, 3 (06) : 673 - 682
  • [69] Phase II-study of PRO95780 plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL)
    Wittebol, S.
    Ferrant, A.
    Wickham, N. W.
    Fehrenbacher, L.
    Durbin-Johnson, B.
    Bray, G. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [70] Yee L, 2009, J CLIN ONCOL, V27
12345678